UCB gets FDA Breakthrough Therapy Designation for CIMZIA in APS pregnancy

UCB says the U.S. FDA granted Breakthrough Therapy Designation to CIMZIA (certolizumab pegol) for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome (APS).